*This report is informational only and not medical advice.* Anesthesia Drips is a specialized clinical reference tool for anesthesiologists and CRNAs, currently ranked #65 in Paid Medical apps (US). Its core value proposition is a "One-Click Reference" system that provides cardiac and anesthesia drip data without requiring manual input of patient weight or concentrations. While it enjoys excellent user sentiment for its clinical specificity, the product faces significant risk due to a decade-long update hiatus on iOS.
Product velocity
Dormant
Daily rank 🇺🇸
#81
Medical · paid
Sentiment
4.8
6 reviews
Nemesis
MDCalc Medical Calculator
The App DNA
What makes this app unique?
For Anesthesiologists, CRNAs, and medical professionals requiring rapid, reliable access to drug infusion data in clinical settings.
What does it look like?
Key features
Comprehensive list of cardiac and anesthesia medications with clinical data
Rapid access to drug information with minimal navigation and no manual data entry
Includes mixing instructions, final concentrations, and basic drug equations
Educational context on drug mechanisms of action
How much does it cost?
The app utilizes a premium one-time purchase model on iOS to position itself as a professional tool, while the Android version appears to be a more frequently updated or newer entry point.
Velocity
Dormant developmentperformanceShow more...
Development appears to be inactive, as the last recorded update on Android occurred in October 2025 with no provided release notes, and the last iOS update dates back to 2015. There is no evidence of a consistent release cadence or recent feature development. The app is classified as a zombie due to the lack of substantive updates over the last several years.
Who built it?
Vargo Anesthesia
4 apps tracked · Medical
User Sentiment
What do users think recently?
Recent user voice shows a thrilled sentiment. Users appreciate clinical specificity & accuracy and ease of use & efficiency.
How are ratings & reviews evolving?
What users say, by theme
- Clinical Specificity & Accuracy
- Ease of Use & Efficiency
- User Interface Navigation
Competition
Competitive landscape for Anesthesia Drips
How's the Medical market?
The rivals identified
By MD Aware, LLC
The dominant clinical decision tool with high update velocity (4 releases in 6 months) that encompasses this app's entire utility within a broader platform.
- Covers 500+ clinical tools across 35+ specialties, whereas target is limited strictly to anesthesia/cardiac drips.
- Features an 'Evidence-Based' section for every calculation citing primary literature, which this app's simplified notes lack.
- Supports institutional SSO and EHR integration, positioning it for hospital-wide use vs. this app's individual retail model.
Unlock the deeper market read.
Access the full report for freeThe Analyst's Read
Key takeaways for Anesthesia Drips
Where is it heading?
- Excellent sentiment regarding clinical specificity (mcg/ml) indicates strong product-market fit.
- iOS version 2.0 has not been updated since 2015, suggesting a lack of active feature investment on the paid platform.
- Android version 1.6.0 shows a 2025 update date, indicating some level of ongoing maintenance.
The SWOT
- Zero-entry workflow (no typing weight/concentration)
- High clinical specificity (mcg/ml and mixing instructions)
- Excellent professional sentiment and trust
- Institutional SSO and EHR integration
- Adding drug-to-drug interaction checkers
- Modernizing UI to match current mobile standards
Next best moves
Synchronize iOS platform parity
+ 2 more prioritized movesFeature gaps
Evidence-Based citations for calculations (available in MDCalc) +3
Bottom line
Anesthesia Drips maintains a loyal professional following by solving the specific pain point of manual data entry in high-stress environments. However, the app is currently in a state of 'maintenance mode' on iOS, and unless it adopts the evidence-based rigor and update frequency of MDCalc, it risks being displaced by broader clinical platforms.
Unlock 3 critical frictions, 3 market threats, 2 more prioritized moves and the analyst’s take.
Access the full report for freeReport last updated